Author

P. Charoentong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Ahmed· 1 shared A. B. Riemer· 1 shared C. Lotsch· 1 shared C. S. Falk· 1 shared C. Springfeld· 1 shared D. Ferber· 1 shared D. Jaeger· 1 shared D. Jager· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ahmed

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

optiPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material

M. Salek, J. D. Forster, J. P. Becker, M. Meyer, P. Charoentong, Y. Lyu, K. Lindner, C. Lotsch, M. Volkmar, F. Momburg, I. Poschke, S. Frohling, M. Schmitz, R. Offringa, M. Platten, , A. B. Riemer

The paper introduces optiPRM, a targeted LC-MS workflow that enhances sensitivity for detecting mutation-derived neoepitopes from limited tumor samples.

Molecular & Cellular Proteomics · Sep 1, 2024Peer-reviewedImmunology

Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer

A. Ahmed, P. Charoentong, R. Klotz, S. Koehler, M. Suarez-Carmona, N. A. Valous, D. Ferber, M. Heikenwaelder, N. Giese, T. Hackert, F. Klupp, M. Schneider, T. Schmidt, C. Springfeld, Y. Tanriver, , N. Halama

This study shows that Langerhans islets in pancreatic tumors promote anti-tumor immunity but impair glycemic control, and identifies T2DM and HbA1c as predictors of chemotherapy response.

bioRxiv · Mar 13, 2021 · PreprintCancer Biology